220127-57-1

Reliable Quality Imatinib mesylate 220127-57-1 Hot Sale with Chinese Manufacturer We supply high quality Imatinib mesylate (CAS 220127-57-1), in stock, factory directly supply to clients, lower prices, more competitiveness.

What is the Imatinib mesylate ?

Imatinib mesylate is Off-white solid, while it's Molecular Formula is C29H31N7O^.CH4O3S. echinocandin antifungal, active against infections with Aspergillus and Candida, inhibits cell wall synthesis

What is the CAS number for Imatinib mesylate ?

The CAS number of Imatinib mesylate is 220127-57-1.

More information of Imatinib mesylate 220127-57-1 are:

What is Imatinib mesylate (220127-57-1) used for?

In May 2001, the FDA approved imatinib as a new cancer drug after a record review time of just 2.5 months. Imatinib was launched as Gleevec in the US for chronic myelogenous leukemia (CML) in blast crisis, accelerated phase or chronic phase after interferon-alpha failure. Imatinib mesylate can be prepared by a four step sequence from a condensation of the 1-(3-pyridyl)ethanone with dimethyl formamide dimethylacetal, followed by successive cyclization with the methyl-nitrophenyl guanidine, hydrogenolysis and condensation with the benzoyl chloride of the methylpiperazine. Imatinib is the first of a new class of anticancer drugs that are specifically designed to target the molecular pathways involved (oncogenic event) in the development of disease. The Brc-Abl oncoprotein is a constitutively active tyrosine kinase that causes CML. Imatinib is a competitive inhibitor of this tyrosine kinase as well as Abl, Kit and the PDGFR kinases It binds to the ATP-binding site of the target kinase and prevents the transfer of phosphate from ATP to the tyrosine residues of various substrates and consequently blocks the proliferation of the leukemic cells. Phase II studies demonstrated that in chronic phase CML, over 90% of the patients had their leukocyte counts return to normal and 56% had a major cytogenic response. No phase III data is currently available. It is clear from the evidence available that imatinib has advantages over IFN-alpha, such as reduced toxicity, more rapid hematological response, higher rate of cytogenic response and oral administration. The drug is well tolerated, producing few side effects, classified as grade 1 nausea, muscle cramps, diarrhea, edema and vomiting. Imatinib is metabolized primarily by the CYP3A4 enzyme system and drugs capable of modulating this system would be expected to modify the patient's exposure. Novartis expects to launch imatinib for the treatment of gastrointestinal stromal tumors in 2002.

InChI:InChI=1/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

Articles related to Imatinib mesylate:

How to get the best price on Imatinib mesylate?

Zibo Yurui Biotechnology Co., Ltd is a quality supplier and manufacturer of Imatinib mesylate . You can buy high quality, low price Imatinib mesylate 220127-57-1 here. Contact us.